GUARDANT HEALTH INC
GHNASDAQTrading Snapshot
- Day Range
- โ
- 52-Week Range
- $74.55 โ $191.05
- Volume (shares)
- โ
- Avg Volume (shares)
- โ
- Shares Outstanding
- 134.2M
- Next Earnings
- 2027-02-18
Fundamentals Snapshot
- Annual Revenue
- $982M
- Last Q Revenue
- $361M
- P/E Ratio
- โ
- P/S Ratio
- 15.3x
- EPS (TTM)
- $-3.68
- Dividend Yield
- โ
- Dilution (1yr)
- +4.0%
GUARDANT HEALTH INC
GHAbout GUARDANT HEALTH INC
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Latest News & Updates

Guardant Health Sees Shield Coverage Boost in 2027, Holds Cash Flow Break-Even Target
Guardant Health NASDAQ: GH expects expanded insurance coverage for its Shield screening test and continued growth in its cancer testing portfolio to support its business in 2027, while maintaining a target of reaching fr

Guardant Health Launches Guardant Revealยฎ Ultra to Deliver Leading Sensitivity in MRD Testing
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. clinical launch of Guardant Revealยฎ Ultra, a new molecular residual disease (MRD) pla

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 13, 2026, the Compensation Committee of Guardant's Board of Directors approved

Guardant Health Prices $500 Million Convertible Senior Notes Offering
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (โGuardant Healthโ) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its offering of $500 million aggregate principal am

Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (โGuardant Healthโ) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $500.0 million aggregate principal amount o

Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360ยฎ Liquid
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new applications for Guardant360ยฎ Liquid designed to help oncologists understand how a patient